Abstract：
OBJECTIVE: Tumors affecting the female genital tract and their treatments have the potential to induce adverse modifications in vaginal health and impact personal aspects of patient\'s lives. Vulvovaginal atrophy is one of the morphological changes observed in individuals with a history of gynecological cancer, influenced both by the biological environment of tumors and the main therapeutic modalities employed. Therefore, the purpose of this study was to identify approaches to treat vulvovaginal atrophy while assessing the impact on the emotional and sexual health of women diagnosed with gynecological cancers.
METHODS: To achieve this goal, a systematic review was conducted following the methodological guidelines outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The databases used for literature research were PubMed and Web of Science.
RESULTS: Initially, 886 articles were obtained. After eliminating duplicates and applying inclusion/exclusion criteria, seven articles were selected for analysis. The period of highest publication activity spanned from 2017 to 2020, with the majority conducted in Italy. Five treatment modalities were identified and categorized as vaginal suppository, oral medication, surgical procedure, CO2 laser therapy, and vaginal dilator. Twenty-four outcomes related to vaginal health and 30 outcomes related to overall, sexual, and emotional quality of life were analyzed.
CONCLUSIONS: In general, all interventions demonstrated the ability to improve vaginal health or, at the very least, the sexual health of patients. Thus, despite limitations, all treatments have the potential to address vulvovaginal atrophy in patients with a history of gynecological cancer.
METHODS: To achieve this goal, a systematic review was conducted following the methodological guidelines outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The databases used for literature research were PubMed and Web of Science.
RESULTS: Initially, 886 articles were obtained. After eliminating duplicates and applying inclusion/exclusion criteria, seven articles were selected for analysis. The period of highest publication activity spanned from 2017 to 2020, with the majority conducted in Italy. Five treatment modalities were identified and categorized as vaginal suppository, oral medication, surgical procedure, CO2 laser therapy, and vaginal dilator. Twenty-four outcomes related to vaginal health and 30 outcomes related to overall, sexual, and emotional quality of life were analyzed.
CONCLUSIONS: In general, all interventions demonstrated the ability to improve vaginal health or, at the very least, the sexual health of patients. Thus, despite limitations, all treatments have the potential to address vulvovaginal atrophy in patients with a history of gynecological cancer.
摘要：
目的：影响女性生殖道的肿瘤及其治疗有可能引起阴道健康的不良改变，并影响患者生活的个人方面。外阴阴道萎缩是在有妇科癌症病史的个体中观察到的形态学变化之一，受肿瘤生物环境和主要治疗方式的影响。因此,这项研究的目的是确定治疗外阴阴道萎缩的方法，同时评估对诊断为妇科癌症的女性的情绪和性健康的影响。
方法：为了实现这一目标，根据系统评价和荟萃分析(PRISMA)首选报告项目概述的方法学指南进行系统评价.用于文献研究的数据库是PubMed和WebofScience。
结果：最初，共获得886篇文章。在消除重复项并应用纳入/排除标准后，选择7篇文章进行分析.出版活动最高的时期是从2017年到2020年，其中大部分在意大利进行。确定了五种治疗方式，并分类为阴道栓剂，口服药物,外科手术,CO2激光治疗,还有阴道扩张器.24个结果与阴道健康相关，30个结果与总体相关，性,并对情绪生活质量进行分析。
结论：一般来说，所有干预措施都显示出改善阴道健康的能力，或者，至少,患者的性健康。因此，尽管有局限性,所有治疗方法都有可能解决有妇科癌症史患者的外阴阴道萎缩.
方法：为了实现这一目标，根据系统评价和荟萃分析(PRISMA)首选报告项目概述的方法学指南进行系统评价.用于文献研究的数据库是PubMed和WebofScience。
结果：最初，共获得886篇文章。在消除重复项并应用纳入/排除标准后，选择7篇文章进行分析.出版活动最高的时期是从2017年到2020年，其中大部分在意大利进行。确定了五种治疗方式，并分类为阴道栓剂，口服药物,外科手术,CO2激光治疗,还有阴道扩张器.24个结果与阴道健康相关，30个结果与总体相关，性,并对情绪生活质量进行分析。
结论：一般来说，所有干预措施都显示出改善阴道健康的能力，或者，至少,患者的性健康。因此，尽管有局限性,所有治疗方法都有可能解决有妇科癌症史患者的外阴阴道萎缩.
